XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
May 31, 2025
Aug. 29, 2025
Nov. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date May 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --05-31    
Entity File Number 001-37863    
Entity Registrant Name BIOMERICA, INC.    
Entity Central Index Key 0000073290    
Entity Tax Identification Number 95-2645573    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 17571 Von Karman Avenue    
Entity Address, City or Town Irvine    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92614    
City Area Code 949    
Local Phone Number 645-2111    
Title of 12(b) Security Common Stock, par value $0.08    
Trading Symbol BMRA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 6.4
Entity Common Stock, Shares Outstanding   2,815,410  
Documents Incorporated by Reference [Text Block] Portions of the registrant’s definitive proxy statement relating to its 2025 annual meeting of stockholders are incorporated by reference in Part III this Annual Report on Form 10-K where indicated. The definitive proxy statement will be filed with the U.S. Securities Exchange Commission within 120 days after the end of the fiscal year to which this report relates.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.08    
Auditor Firm ID 200    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Biomerica, Inc. (the “Company”) as of May 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of May 31, 2025 and 2024, and the consolidated results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.    
Auditor Name HASKELL & WHITE LLP    
Auditor Location Irvine, California